Drugs / EYP-1901
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials · 2 missed | ||||||
| Phase 2 | NCT06099184 | Jan → Oct 2024 | diabetic macular edema | EyePoint Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05383209 | Sep 2022 → Feb 2024 | diabetic retinopathy | EyePoint Pharmaceuticals, Inc. | Completed | Missed primary |
| Phase 2 | NCT05381948 | Jun 2022 → Nov 2023 | wet macular degeneration | EyePoint Pharmaceuticals, Inc. | Completed | Missed primary |
| Phase 34 trials · 1 met primary | ||||||
| Phase 3 | NCT07449936 | Feb 2026 → Oct 2027 expected | diabetic macular edema | EyePoint Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07449923 | Feb 2026 → Oct 2027 expected | diabetic macular edema | EyePoint Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06683742 | Nov 2024 → Oct 2026 expected | wet macular degeneration | EyePoint Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06668064 | Oct 2024 → Aug 2026 overdue | wet macular degeneration | EyePoint Pharmaceuticals, Inc. | Active not recruiting | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EYP-1901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06099184 ↗ |
| Action | Inhibit | “EYP-1901, a Tyrosine Kinase Inhibitor (TKI)” NCT05383209 ↗ |
| Route | Intravitreal | “Intravitreal Injection” NCT07449923 ↗ |